Tandem Diabetes Care Announces FDA Clearance For The T:slim X2 Insulin Pump To Bolus Using The T:connect Mobile App

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced U.S. Food and Drug Administration (FDA) clearance of bolus insulin dosing on the t:slim X2 insulin pump using the t:connect mobile app. This represents the first-ever FDA-cleared smartphone application capable of initiating insulin delivery on both iOS and Android operating systems. The updated t:connect mobile app is designed to offer t:slim X2 insulin pump users the ability to program and cancel bolus insulin requests through the convenience of their compatible smartphone.

When released, this new feature will be offered in . . .